HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury
Seminars in Cancer Biology · 2025-08 · 113 · 25-38
DOI: 10.1016/j.semcancer.2025.05.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2025-08. Verfasst von Kenneth K W To und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. Electronic address: kennethto@cuhk.edu.hk. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Cardiotoxicity, Myocardial Reperfusion Injury, Cardiotonic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Histone deacetylase inhibitors (HDACIs) are epigenetic drugs that regulate the acetylation status of histones and non-histone proteins, thereby leading to chromatin remodeling and transcriptional regulation of key apoptotic and cell cycle regulatory genes. There are currently five HDACIs clinically approved by the major regulatory authorities for treating hematological cancers, primarily as monotherapy. While HDACIs have been particularly effective in T-cell lymphomas, their clinical efficacies have not yet extended to solid tumors. The development of HDACIs continues, including for the treatment of a non-malignant conditions, with givinostat recently approved by the US FDA. However, the early development of HDACIs was limited by concerns about cardiotoxicity including QT interval prolongation. Yet, paradoxically, the latest research suggests some cardioprotective effect of HDACIs in ischemic heart disease or heart failure. This review presents the latest update about the cardiotoxicity of the clinically approved HDACIs. The mechanisms leading to HDACI-induced cardiotoxic adverse events and clinical strategies for their management are discussed. We will also deliberate the potential repurposing use of HDACIs and their HDAC isoform selectivity for treating ischemia-reperfusion cardiac muscle injury, cardiac hypertrophy, and fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. Electronic address: kennethto@cuhk.edu.hk.
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
- Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: seb2227@cumc.columbia.edu.
Zitieren
APA
To, K. K. W., Tolu, S. S., Wang, L., Zhang, H., Cho, W. C., & Bates, S. E. (2025). HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury. Seminars in Cancer Biology, 113, 25-38. https://doi.org/10.1016/j.semcancer.2025.05.008
Vancouver
To KKW, Tolu SS, Wang L, Zhang H, Cho WC, Bates SE. HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury. Seminars in Cancer Biology. 2025;113:25-38. doi:10.1016/j.semcancer.2025.05.008
BibTeX
@article{To2025,
author = {To, Kenneth K W and Tolu, Seda S and Wang, Longling and Zhang, Hang and Cho, William C and Bates, Susan E},
title = {HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury},
journal = {Seminars in Cancer Biology},
year = {2025},
volume = {113},
pages = {25--38},
doi = {10.1016/j.semcancer.2025.05.008}
}
EUVIMED